Antiepileptic drugs for seizure control in people with neurocysticercosis
- PMID: 31608991
- PMCID: PMC6790915
- DOI: 10.1002/14651858.CD009027.pub3
Antiepileptic drugs for seizure control in people with neurocysticercosis
Update in
-
Antiepileptic drugs for seizure control in people with neurocysticercosis.Cochrane Database Syst Rev. 2021 Nov 1;11(11):CD009027. doi: 10.1002/14651858.CD009027.pub4. Cochrane Database Syst Rev. 2021. PMID: 34723391 Free PMC article. Review.
Abstract
Background: Neurocysticercosis is the most common parasitic infection of the brain. Epilepsy is the most common clinical presentation, though it may also present with headache, symptoms of raised intracranial pressure, hydrocephalus and ocular symptoms depending upon the localisation of the parasitic cysts. Anthelmintic drugs, anti-oedema drugs, such as steroids, and antiepileptic drugs (AEDs) form the mainstay of treatment.This is an updated version of the original Cochrane Review published in 2015, Issue 10.
Objectives: To assess the effects (benefits and harms) of AEDs for the primary and secondary prevention of seizures in people with neurocysticercosis.For the question of primary prevention, we examined whether AEDs reduce the likelihood of seizures in patients who have neurocysticercosis but have not had a seizure.For the question of secondary prevention, we examined whether AEDs reduce the likelihood of further seizures in patients who have had at least one seizure due to neurocysticercosis.As part of primary prevention studies, we also aimed to examine which AED has been found to be beneficial in people with neurocysticercosis in terms of duration, dose and side-effect profile.
Search methods: For the latest update of this review, we searched the following databases on 8 July 2019: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to July 05, 2019) and LILACS (1982- ). CRS Web includes the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), and randomised or quasi-randomised, controlled trials from Embase, ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (ICTRP). We also checked the references lists of identified studies, and contacted experts in the field and colleagues to search for additional studies and for information about ongoing studies.
Selection criteria: Randomised and quasi-randomised controlled trials.Single-blind, double-blind or unblinded studies were eligible for inclusion.
Data collection and analysis: Two review authors screened all citations for eligibility (MS screened the initially identified 180 citations, MF and BDM screened the 48 citations identified for the purpose of this update).Two review authors independently extracted data and evaluated each study for risk of bias.
Main results: We did not find any trials that investigated the role of AEDs in preventing seizures among people with neurocysticercosis, presenting with symptoms other than seizures.We did not find any trials that evaluated evaluating individual AEDs in people with neurocysticercosis.We found one trial, comparing two AEDs in people with solitary neurocysticercosis with seizures. However, we excluded this study from the review as it was of poor quality.We found four trials that compared the efficacy of short term versus longer term AED treatment for people with solitary neurocysticercosis (identified on computed tomography (CT) scan) presenting with seizures. In total, 466 people were enrolled. These studies compared various AED treatment durations, six, 12 and 24 months. The risk of seizure recurrence with six months treatment compared with 12 to 24 months treatment was not statistically significant (odds ratio (OR) 1.34 (95% confidence interval (CI) 0.73 to 2.47; three studies, 360 participants; low-certainty evidence)). The risk of seizure recurrence with six to 12 months compared with 24 months treatment was not statistically significant (OR 1.36 (95% CI 0.72 to 2.57; three studies, 385 participants; low-certainty evidence)).Two studies co-related seizure recurrence with CT findings and suggested that persistent and calcified lesions had a higher recurrence risk and suggest longer duration of treatment with AEDs. One study reported no side effects, while the rest did not comment on side effects of drugs. None of the studies addressed the quality of life of the participants.These studies had certain methodological deficiencies such as a small sample size and a possibility of bias due to lack of blinding, which affect the results of this review.
Authors' conclusions: Despite neurocysticercosis being the most common cause of epilepsy worldwide, there is currently no evidence available regarding the use of AEDs as seizure prophylaxis among people presenting with symptoms other than seizures. For those presenting with seizures, there is no reliable evidence regarding the duration of treatment required. There is therefore a need for large scale randomised controlled trials to address these questions.
Conflict of interest statement
MF: none known MS: none known TS: none known AM: none known BDM has received funding from the NIHR, Wellcome Trust, Academy of Medical Sciences, British Medical Association.
Figures
![1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6790915/bin/nCD009027-AFig-FIG01.gif)
![2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6790915/bin/nCD009027-AFig-FIG02.gif)
![3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6790915/bin/nCD009027-AFig-FIG03.gif)
![4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6790915/bin/nCD009027-AFig-FIG04.gif)
![5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6790915/bin/nCD009027-AFig-FIG05.gif)
![6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6790915/bin/nCD009027-AFig-FIG06.gif)
![1.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6790915/bin/nCD009027-CMP-001-01.gif)
![2.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6790915/bin/nCD009027-CMP-002-01.gif)
Similar articles
-
Antiepileptic drugs for seizure control in people with neurocysticercosis.Cochrane Database Syst Rev. 2021 Nov 1;11(11):CD009027. doi: 10.1002/14651858.CD009027.pub4. Cochrane Database Syst Rev. 2021. PMID: 34723391 Free PMC article. Review.
-
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.Cochrane Database Syst Rev. 2022 Apr 1;4(4):CD011412. doi: 10.1002/14651858.CD011412.pub4. Cochrane Database Syst Rev. 2022. PMID: 35363878 Free PMC article. Review.
-
Antiepileptic drugs for the primary and secondary prevention of seizures after stroke.Cochrane Database Syst Rev. 2022 Feb 7;2(2):CD005398. doi: 10.1002/14651858.CD005398.pub4. Cochrane Database Syst Rev. 2022. PMID: 35129214 Free PMC article. Review.
-
Rapid versus slow withdrawal of antiepileptic drugs.Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD005003. doi: 10.1002/14651858.CD005003.pub4. Cochrane Database Syst Rev. 2022. PMID: 35005782 Free PMC article. Review.
-
Antiepileptic drugs for seizure control in people with neurocysticercosis.Cochrane Database Syst Rev. 2015 Oct 12;(10):CD009027. doi: 10.1002/14651858.CD009027.pub2. Cochrane Database Syst Rev. 2015. PMID: 26455722 Review.
Cited by
-
Global research on cysticercosis and neurocysticercosis: A bibliometric analysis.Front Vet Sci. 2023 Apr 11;10:1156834. doi: 10.3389/fvets.2023.1156834. eCollection 2023. Front Vet Sci. 2023. PMID: 37113561 Free PMC article.
-
Antiepileptic drugs for seizure control in people with neurocysticercosis.Cochrane Database Syst Rev. 2021 Nov 1;11(11):CD009027. doi: 10.1002/14651858.CD009027.pub4. Cochrane Database Syst Rev. 2021. PMID: 34723391 Free PMC article. Review.
-
The effectiveness of anti-inflammatory and anti-seizure medication for individuals with single enhancing lesion neurocysticercosis: A meta-analysis and expert group-based consensus recommendations.PLoS Negl Trop Dis. 2021 Mar 31;15(3):e0009193. doi: 10.1371/journal.pntd.0009193. eCollection 2021 Mar. PLoS Negl Trop Dis. 2021. PMID: 33788843 Free PMC article.
-
Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Am J Trop Med Hyg. 2018 Apr;98(4):945-966. doi: 10.4269/ajtmh.18-88751. Am J Trop Med Hyg. 2018. PMID: 29644966 Free PMC article. No abstract available.
References
References to studies included in this review
Gupta 2002 {published data only}
-
- Gupta M, Agarwal P, Khwaja GA, Chowdhury D, Sharma B, Bansal J, et al. Randomized prospective study of outcome of short term antiepileptic treatment in small single enhancing CT lesion in brain. Neurology India 2002;50(2):145‐7. [PUBMED: 12134176] - PubMed
Singhi 2003 {published data only}
Thussu 2002 {published data only}
-
- Thussu A, Arora A, Prabhakar S, Lal V, Sawhney IM. Acute symptomatic seizures due to single CT lesions: how long to treat with antiepileptic drugs?. Neurology India 2002;50(2):141‐4. [PUBMED: 12134175] - PubMed
References to studies excluded from this review
Chang 1998 {published data only}
-
- Chang GY. Tiagabine HCl may be effective in complex partial epilepsy due to neurocysticercosis. Neurology 1998;50(4 Suppl 4):A200, Abstract no: P04.003.
Kaushal 2006 {published data only}
-
- Kaushal S, Rani A, Chopra SC, Singh G. Safety and efficacy of clobazam versus phenytoin sodium in the anti‐epileptic drug treatment of solitary cysticercus granulomas. Neurology India June 2006;54(2):157‐60. [PUBMED: 16804259] - PubMed
Lanchote 2002 {published data only}
-
- Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM. Pharmocokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Therapeutic Drug Monitoring 2002;24(3):338‐45. [PUBMED: 12021623] - PubMed
Additional references
Abba 2010
Daniels 2006
-
- Daniels TL, Moore TA. Neurocysticercosis in Kansas. Annals of Internal Medicine 2006;144(2):150‐2. - PubMed
DeGiorgio 2004
Del Brutto 1992
-
- Brutto OH, Santibañez R, Noboa CA, Aguirre R, Díaz E, Alarcón TA. Epilepsy due to neurocysticercosis. Analysis of 203 patients. Neurology 1992;42:389‐92. - PubMed
Del Brutto 1996
-
- Brutto OH, Campos X. Discontinuation of antiepileptic drugs in patients with calcified neurocysticercosis. Journal of Epilepsy 1996;9(4):231‐3.
Del Brutto 2001
Del Brutto 2005
-
- Brutto OH, Santibáñez R, Idrovo L, Rodrìguez S, Díaz‐Calderón E, Navas C, et al. Epilepsy and neurocysticercosis in Atahualpa: a door to door survey in rural coastal Ecuador. Epilepsia 2005;46(4):583‐7. - PubMed
Dhawan 2011
-
- Dhawan VK. Pediatric Nnurocysticercosis. http://emedicine.medscape.com/article/999053‐overview#a0199 2011 (accessed 22 May 2014).
Ferreira 2002
-
- Ferreira LS, Li LM, Zanardi VA, Guerreiro MM. Number and viability of parasite influence seizure frequency in children with neurocysticercosis. Arquivos de Neuropsiquiatria 2002;60(4):909‐11. - PubMed
García 2002
GRADEPro 2004 [Computer program]
-
- Brozek J, Oxman A, Schunemann H. GRADEpro GDT. Version accessed 6 August 2016. Hamilton (ON): McMaster University (developed by Evidence Prime).. Available at gradepro.org.. GRADE Working Group, 2004.
Hauser 1992
Higgins 2011
-
- Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org/.
Lefebvre 2011
-
- Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org/.
Murthy 2007
-
- Murthy J, Rajshekhar G. Economic evaluation of seizures associated with solitary cysticercus granuloma. Neurology India 2007;55(1):42‐5. - PubMed
Pal 2000
Palacio 1998
-
- Palacio LG, Jiménez L Garcia HH, Jiménez ME, Sánchez JL, Noh J, et al. Neurocysticercosis in persons with epilepsy in Medellin, Colombia. Epilepsia 1998;39(12):1334‐9. - PubMed
Pradhan 2000
-
- Pradhan S, Kathuria MK, Gupta RK. Perilesional gliosis and seizure outcome:a study based on magnetization transfer magnetic resonance imaging in patients with neurocysticercosis. Annals of Neurology 2000;48(2):181‐7. - PubMed
Rajshekhar 2003
-
- Rajshekhar V. Solitary cerebral cysticercus granuloma. Epilepsia 2003;44(Suppl 1):25‐8. - PubMed
Rajshekhar 2004
-
- Rajshekhar V, Jeyaseelan L. Seizure outcome in patients with a solitary cerebral cysticercus granuloma. Neurology 2004;62(12):2236‐40. - PubMed
Rajshekhar 2006
-
- Rajshekhar V, Raghava MV, Prabhakaran V, Oommen A, Muliyil J. Active epilepsy as an index of burden of neurocysticercosis in Vellore district, India. Neurology 2006;67(12):2135‐9. - PubMed
RevMan 2014 [Computer program]
-
- The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sander 1996
Singhi 2000
-
- Singhi P, Ray M, Singhi S, Khandelwal N. Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. Journal of Child Neurology 2000;15(4):207‐13. - PubMed
Zafar 2013
-
- Zafar MJ. Neurocysticercosis. http://emedicine.medscape.com/article/1168656‐overview#a0156 2013 (accessed 22 May 2014).
References to other published versions of this review
Sharma 2011
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources